Building effective multimodal care for obesity and comorbidities in the GLP-1 therapy era

Postpartum initiation of GLP-1 receptor agonists among commercially insured women in the us

New triple agonist retatrutide produces substantial weight loss and improvements in blood sugar control in people living with obesity and type 2 diabetes – TRIUMPH-2 study

Higher GLP-1 costs lead to lower adherence